🇺🇸 FDA

Drug profile · INN

thalidomide

THALIDOMIDE BMS (PREVIOUSLY THALIDOMIDE CELGENE)

approved L04AX02
US status
approved
Patents linked
5
News articles
0

Quick answer

thalidomide (THALIDOMIDE BMS (PREVIOUSLY THALIDOMIDE CELGENE)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN thalidomide
Brand THALIDOMIDE BMS (PREVIOUSLY THALIDOMIDE CELGENE)
Route ORAL
Formulation CAPSULE
ATC code L04AX02

Related patents

Search patents →

  1. US 10836721

    Thalidomide analogs and methods of use

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10730835

    Thalidomide analogs and methods of use

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8716315

    Analogs of thalidomide as potential angiogenesis inhibitors

    Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7973057

    Thalidomide analogs

    Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7320991

    Analogs of thalidomide as potential angiogenesis inhibitors

    Expires Mon Jan 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is thalidomide?

thalidomide (THALIDOMIDE BMS (PREVIOUSLY THALIDOMIDE CELGENE)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for thalidomide?

THALIDOMIDE BMS (PREVIOUSLY THALIDOMIDE CELGENE) is a marketed brand name for thalidomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of thalidomide?

thalidomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.